Pharmacokinetic interaction between febuxostat and morin in rats

Expert Opinion on Drug Metabolism and Toxicology

Volumn 10, Issue 3, 2014, Pages 307-312

  Sahu, Kapendra ^a   Siddiqui, Anees A ^a   Shaharyar, Mohammad ^a   Malik, Sachin ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Drug flavonoid interaction; Febuxostat; Morin; Pharmacokinetics; Ultra performance liquid chromatography

Indexed keywords

FEBUXOSTAT; FLAVONOID; MORIN; MULTIDRUG RESISTANCE PROTEIN; THIAZOLE DERIVATIVE;

ANIMAL; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG INTERACTION; HALF LIFE TIME; MALE; METABOLISM; ORAL DRUG ADMINISTRATION; RAT; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FLAVONOIDS; HALF-LIFE; MALE; P-GLYCOPROTEIN; RATS; RATS, WISTAR; THIAZOLES;

EID: 84894210771     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2014.885017     Document Type: Article

References (20)

1. Schumacher HR Jr. Febuxostat: A nonpurine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout. Expert Opin Investig Drugs 2005;14:893-3
2. Wang H, Deng P, Chen X, et al. Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of febuxostat in human plasma. Biomed Chromatogr 2010;27:34-8
3. Yu KH. Febuxostat: A novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout. Recent Pat Inflamm Allergy Drug Discov 2007;1:69-5
4. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61
5. Mukoyoshi M, Nishimura S, Hoshide S, et al. In vitro drug-drug interaction studies with febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: Plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition. Xenobiotica 2008;38:496-10 . This study highlights needed information about CYP enzymes participating in the metabolism of febuxostat and potential inhibitory effects of febuxostat on typical CYP reactions.
6. Sahu K SM, Siddiqui Anees A. Establishment of inherent stability of febuxostat and development of a validated stability-indicating method by UPLC according to ICH requirement. Med Chem Res 2013;22:1641-7. This important study demonstrates the validated UPLC method for febuxostat.
7. Cook NC, Samman S. Flavonoidschemistry, metabolism, cardioprotective effects, and dietary sources. J Nutr Biochem 1996;7:66-76
8. Middleton E Jr, Kandaswami C, Theoharides TC. The effect of plant flavonoids on mammalian cells: Implications for inflammation, heart disease, and cancer. Pharmcol Rev 2000;52:673-751. This article describes that the flavonoids, as dietary supplements, have great potential to modulate the activity of CYPs.
9. Critchfield JW, Welsh CJ, Phang JM, et al. Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Activation of Pglycoprotein as a putative mechanism. Biochem Pharmacol 1994;48:1437-45
10. Zhang S, Morris ME. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on Pglycoproteinmediated transport. J Pharmacol Exp Ther 2003;304:1258-67 . This noteworthy study reviewed the inhibitory effect of the morin (a flavonoid) on P-gp-mediated transport.
11. Choi BC, Choi JS, Han HK. Altered pharmacokinetics of paclitaxel by the concomitant use of morin in rats. Int J Pharm 2006;323:81-5. This study investigated the effects of orally administered morin, an inhibitor of CYP3A and P-gp, on the pharmacokinetics of orally and intravenously administered paclitaxel in rats.
12. Singh SP, Wahajuddin Raju KS, et al. Reduced bioavailability of tamoxifen and its metabolite 4-hydroxytamoxifen after oral administration with biochanin A (an isoflavone) in rats. Phytother Res 2011;26:303-7
13. Kitagawa S, Nabekura T, Takahashi T, et al. Structure-activity relationships of the inhibitory effects of flavonoids on P-glycoprotein-mediated transport in KB-C2 cells. Biol Pharm Bull 2005;28:2274-8
14. Hodek P, Trefil P, Stiborova M. Flavonoids - potent and versatile biologically active compounds interacting with cytochromes P450. Chem Biol Interact 2002;139:1-21 . This important study demonstrates that the use of morin could modulate the activity of metabolic enzymes, including CYPs.
15. Eagling VA, Profit L, Back DJ. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br J Clin Pharmacol 1999;48:543-52
16. Sahu K, Shaharyar M, Siddiqui AA. Effect of Morin on pharmacokinetics of Piracetam in rats, in vitro enzyme kinetics and metabolic stability assay using rapid UPLC method. Drug Test Anal 2013;5:581-8
17. Takeda Pharmaceuticals America. Uloric (febuxostat) tablets prescribing information. Deerfield, II; 2009 (Reference ID: 2898038)
18. Choi JS, Kang KW. Enhanced tamoxifen bioavailability after oral administration of tamoxifen in rats pretreated with naringin. Arch Pharm Res 2008;31:1631-6
19. Fakhoury M, Litalien C, Medard Y, et al. Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age. Drug Metab Dispos 2005;33:1603-7
20. Wang E, Lew K, Barecki M, et al. Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4. Chem Res Toxicol 2001;14:1596-603